Joshua Schimmer

Regeneron Shares Advance on Sanofi’s Plan to Buy Stock

Regeneron Pharmaceuticals Inc., maker of the eye medicine Eylea, rose the most in three weeks on drug-development partner Sanofi’s plans to raise its stake in the company by buying shares on the stock market.

Profit Squeeze Hits Drugmakers as Europe Crisis Leads to Cuts

Europe’s financial crisis is leading Johnson & Johnson , Sanofi-Aventis SA and Merck & Co. to lower forecasts and reduce spending, adding pressure on drugmakers already squeezed by generic competition.

Amylin May Draw Suitors After Rejecting Bristol-Myers

Amylin Pharmaceuticals Inc., maker of the diabetes drug Bydureon, may draw bids from other suitors after rejecting a $3.5 billion unsolicited takeover offer from Bristol-Myers Squibb Co. earlier this year.

Orexigen's Diet Pill Victory at Panel Shows Benefit of Being Last at FDA

Orexigen Therapeutics Inc. ’s success in winning the first U.S. panel recommendation for a long-sought prescription diet pill led its shares to almost double and shows the company benefited from its rivals’ earlier difficulties.

Gilead Bets on Hepatitis C Data to Back Pharmasset Deal

Gilead Sciences Inc., after paying $10.8 billion for the developer of an experimental hepatitis C drug, will soon give investors a better sense of whether its largest-deal ever is going to pay off.

Sanofi Bid for Genzyme Bid May Need to Be Higher Than $80 to Win Investors

Sanofi-Aventis SA may have to pay at least $80 a share, or $21.3 billion, to acquire genetic-disease drugmaker Genzyme Corp. as activist directors drive up the price, investors in the U.S. biotechnology company say.

Amylin, Takeda Suspend Clinical Activities in Obesity Trial

Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. suspended an obesity-treatment trial as they investigate a safety concern from a previous study.

MannKind Falls Most in Six Months on Plan to Sell More Shares, Add Debt

MannKind Corp., a biotechnology company with a diabetes drug in late-stage testing, fell the most in almost a year after saying it will sell more shares to raise money.

Gilead HIV Breakthrough of the Year Stymied by $12,000 Cost, Side Effects

Gilead Sciences Inc.’s Truvada topped Time magazine’s list of medical breakthroughs for 2010 after a study showed it may achieve a goal pursued by scientists for a quarter-century: a pill to prevent HIV infection.

Amylin Options Signal 26% Gain After Bristol-Myers Bid: Real M&A

Options traders are betting potential acquirers from AstraZeneca Plc to Bristol-Myers Squibb Co. will have to spend 26 percent more than its current price to buy Amylin Pharmaceuticals Inc.

"Presumably, they were unable to agree upon a reasonable purchase price, and Sanofi can't go hostile given the standstill agreement."

- Joshua Schimmer on Feb 11, 2013

New York

Tim Anderson

Osaka

Boston

Bill Gates Retakes World’s Richest Title From Carlos Slim

Obama Joins Erdogan in Latest Demand for Assad Ouster

European Stocks Pare Decline as Lloyds Shares Advance

Singapore Air Shares Slump After Wider Operating Loss

Asia Stock Index Poised for Weekly Gain as Topix Climbs